Cargando…

Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study

BACKGROUND: The rare incidence of esophageal neuroendocrine carcinoma (NEC) and limited treatment experience result in insufficient clinical observations and unsuitable guidelines for its management. AIM: To investigate the prognostic value of pretreatment contrast-enhanced computed tomography (CT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yue, Hou, Ping, Zha, Kai-Ji, Wang, Feng, Zhou, Kun, He, Wei, Gao, Jian-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445868/
https://www.ncbi.nlm.nih.gov/pubmed/32884225
http://dx.doi.org/10.3748/wjg.v26.i31.4680
_version_ 1783574067496878080
author Zhou, Yue
Hou, Ping
Zha, Kai-Ji
Wang, Feng
Zhou, Kun
He, Wei
Gao, Jian-Bo
author_facet Zhou, Yue
Hou, Ping
Zha, Kai-Ji
Wang, Feng
Zhou, Kun
He, Wei
Gao, Jian-Bo
author_sort Zhou, Yue
collection PubMed
description BACKGROUND: The rare incidence of esophageal neuroendocrine carcinoma (NEC) and limited treatment experience result in insufficient clinical observations and unsuitable guidelines for its management. AIM: To investigate the prognostic value of pretreatment contrast-enhanced computed tomography (CT) characteristics in patients with esophageal NEC. METHODS: Seventy-seven esophageal NEC patients who received contrast-enhanced CT at two hospitals were enrolled in this study from June 2014 to December 2019. The clinical features and image characteristics were recorded accordingly. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank test, and multivariate analysis was carried out with a Cox proportional hazards model. RESULTS: The multivariate analysis performed using the Cox proportional hazards model showed that N stage, adjuvant chemotherapy, and degree of enhancement were independent prognostic factors for overall survival (OS). Meanwhile, adjuvant chemotherapy was an independent prognostic factor for progression-free survival (PFS). The hazard ratios (HRs) of N stage, adjuvant chemotherapy, and degree of enhancement (mild vs moderate/marked) for OS were 0.426 (P = 0.024), 3.862 (P = 0.006), and 2.169/0.809 (P = 0.037), respectively. The HR of adjuvant chemotherapy for PFS was 6.432 (P < 0.001). Adjuvant chemotherapy was significantly associated with degree of enhancement (P = 0.018). CONCLUSION: Adjuvant chemotherapy is an independent prognostic factor for OS and PFS. Additionally, N stage and degree of enhancement are prognostic factors for OS in patients with esophageal NEC.
format Online
Article
Text
id pubmed-7445868
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-74458682020-09-02 Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study Zhou, Yue Hou, Ping Zha, Kai-Ji Wang, Feng Zhou, Kun He, Wei Gao, Jian-Bo World J Gastroenterol Retrospective Study BACKGROUND: The rare incidence of esophageal neuroendocrine carcinoma (NEC) and limited treatment experience result in insufficient clinical observations and unsuitable guidelines for its management. AIM: To investigate the prognostic value of pretreatment contrast-enhanced computed tomography (CT) characteristics in patients with esophageal NEC. METHODS: Seventy-seven esophageal NEC patients who received contrast-enhanced CT at two hospitals were enrolled in this study from June 2014 to December 2019. The clinical features and image characteristics were recorded accordingly. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank test, and multivariate analysis was carried out with a Cox proportional hazards model. RESULTS: The multivariate analysis performed using the Cox proportional hazards model showed that N stage, adjuvant chemotherapy, and degree of enhancement were independent prognostic factors for overall survival (OS). Meanwhile, adjuvant chemotherapy was an independent prognostic factor for progression-free survival (PFS). The hazard ratios (HRs) of N stage, adjuvant chemotherapy, and degree of enhancement (mild vs moderate/marked) for OS were 0.426 (P = 0.024), 3.862 (P = 0.006), and 2.169/0.809 (P = 0.037), respectively. The HR of adjuvant chemotherapy for PFS was 6.432 (P < 0.001). Adjuvant chemotherapy was significantly associated with degree of enhancement (P = 0.018). CONCLUSION: Adjuvant chemotherapy is an independent prognostic factor for OS and PFS. Additionally, N stage and degree of enhancement are prognostic factors for OS in patients with esophageal NEC. Baishideng Publishing Group Inc 2020-08-21 2020-08-21 /pmc/articles/PMC7445868/ /pubmed/32884225 http://dx.doi.org/10.3748/wjg.v26.i31.4680 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Zhou, Yue
Hou, Ping
Zha, Kai-Ji
Wang, Feng
Zhou, Kun
He, Wei
Gao, Jian-Bo
Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title_full Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title_fullStr Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title_full_unstemmed Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title_short Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study
title_sort prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: a multi-center follow-up study
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445868/
https://www.ncbi.nlm.nih.gov/pubmed/32884225
http://dx.doi.org/10.3748/wjg.v26.i31.4680
work_keys_str_mv AT zhouyue prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT houping prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT zhakaiji prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT wangfeng prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT zhoukun prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT hewei prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy
AT gaojianbo prognosticvalueofpretreatmentcontrastenhancedcomputedtomographyinesophagealneuroendocrinecarcinomaamulticenterfollowupstudy